Radiological Variability in Pancreatic Neuroendocrine Neoplasms: A 10-Year Single-Center Study on Atypical Presentations and Diagnostic Challenges

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Feb 26

PMID 40002909

Authors

Eleanor Danek

Helen Kavnoudias

Catriona McLean

Jan F Gerstenmaier

Bruno Di Muzio

Affiliations

Soon will be listed here.

Abstract

Pancreatic neuroendocrine neoplasms (PNENs) are rare but clinically significant tumors with variable radiological presentations that complicate diagnosis. While typical PNENs are well characterized, atypical features, such as cystic or hypoenhancing patterns, are less understood and can lead to diagnostic delays or misdiagnosis. This study aimed to evaluate atypical radiological presentations of PNENs, focusing on their impact on diagnostic pathways and differentiation from other pancreatic pathologies. A retrospective review was conducted of all PNEN cases diagnosed at a single tertiary center between 2010 and 2020. Cases with histopathological confirmation and available cross-sectional imaging were included. Radiological features were categorized as typical (solid and hyperenhancing) or atypical (cystic and hypoenhancing). Demographic, radiological, and pathological data were analyzed. Comparisons between typical and atypical PNENs were performed using descriptive and inferential statistics. Among 77 PNEN cases, 39 met the inclusion criteria. Atypical radiological presentations were identified in 46% of cases, including cystic (18%) and hypoenhancing (28%) lesions. Hypoenhancing PNENs were significantly more likely to present with advanced disease (54% vs. 14% in typical PNENs, = 0.016). In contrast, none of the cystic PNENs exhibited advanced disease. Atypical PNENs posed greater diagnostic challenges, with alternative diagnoses initially considered in 64% of hypoenhancing and 43% of cystic cases compared to 10% of typical PNENs ( = 0.0042). Atypical PNENs, particularly hypoenhancing lesions, present significant diagnostic challenges and are more likely to be associated with advanced disease. These findings highlight the need for improved recognition of atypical imaging patterns and more precise diagnostic strategies. However, the retrospective design and small cohort size limit the generalizability of our findings. Further multicenter studies are warranted to refine the imaging criteria and optimize the differentiation from other pancreatic neoplasms.

References

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

Milan S, Yeo C . Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2011; 24(1):46-55. DOI: 10.1097/CCO.0b013e32834c554d. View

Atiq M, Bhutani M, Bektas M, Lee J, Gong Y, Tamm E . EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci. 2011; 57(3):791-800. DOI: 10.1007/s10620-011-1912-7. View

Lee L, Ito T, Jensen R . Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther. 2018; 18(9):837-860. PMC: 6283410. DOI: 10.1080/14737140.2018.1496822. View

Paiella S, Marchegiani G, Miotto M, Malpaga A, Impellizzeri H, Montagnini G . Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity Results from a Single-Center Surgical Series. Neuroendocrinology. 2017; 106(3):234-241. DOI: 10.1159/000477849. View

Maggino L, Schmidt A, Kading A, Westermark S, Ceppa E, Falconi M . Reappraisal of a 2-Cm Cut-off Size for the Management of Cystic Pancreatic Neuroendocrine Neoplasms: A Multicenter International Study. Ann Surg. 2019; 273(5):973-981. DOI: 10.1097/SLA.0000000000003508. View

Oberg K, Knigge U, Kwekkeboom D, Perren A . Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii124-30. DOI: 10.1093/annonc/mds295. View

Buetow P, Parrino T, Buck J, Pantongrag-Brown L, Ros P, Dachman A . Islet cell tumors of the pancreas: pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. AJR Am J Roentgenol. 1995; 165(5):1175-9. DOI: 10.2214/ajr.165.5.7572498. View

Baker M, Knuth J, DeWitt J, LeBlanc J, Cramer H, Howard T . Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology. J Gastrointest Surg. 2007; 12(3):450-6. DOI: 10.1007/s11605-007-0219-7. View

10.

Inzani F, Petrone G, Rindi G . The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin North Am. 2018; 47(3):463-470. DOI: 10.1016/j.ecl.2018.04.008. View

11.

Nakashima Y, Ohtsuka T, Nakamura S, Mori Y, Nakata K, Miyasaka Y . Clinicopathological characteristics of non-functioning cystic pancreatic neuroendocrine tumors. Pancreatology. 2018; 19(1):50-56. DOI: 10.1016/j.pan.2018.11.010. View

12.

Hallet J, Law C, Cukier M, Saskin R, Liu N, Singh S . Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2014; 121(4):589-97. DOI: 10.1002/cncr.29099. View

13.

McKenna L, Edil B . Update on pancreatic neuroendocrine tumors. Gland Surg. 2014; 3(4):258-75. PMC: 4244504. DOI: 10.3978/j.issn.2227-684X.2014.06.03. View

14.

Kawamoto S, Johnson P, Shi C, Singhi A, Hruban R, Wolfgang C . Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. AJR Am J Roentgenol. 2013; 200(3):W283-90. PMC: 4048027. DOI: 10.2214/AJR.12.8941. View

15.

Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7):844-860. DOI: 10.1016/j.annonc.2020.03.304. View

16.

Ahrendt S, Komorowski R, Demeure M, Wilson S, Pitt H . Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible?. J Gastrointest Surg. 2002; 6(1):66-74. DOI: 10.1016/s1091-255x(01)00020-8. View

17.

Goh B, Ooi L, Tan Y, Cheow P, Chung Y, Chow P . Clinico-pathological features of cystic pancreatic endocrine neoplasms and a comparison with their solid counterparts. Eur J Surg Oncol. 2006; 32(5):553-6. DOI: 10.1016/j.ejso.2006.02.017. View

18.

Figueiredo F, Giovannini M, Monges G, Bories E, Pesenti C, Caillol F . EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc. 2009; 70(5):907-14. DOI: 10.1016/j.gie.2009.05.020. View

19.

Khanna L, Prasad S, Sunnapwar A, Kondapaneni S, Dasyam A, Tammisetti V . Pancreatic Neuroendocrine Neoplasms: 2020 Update on Pathologic and Imaging Findings and Classification. Radiographics. 2020; 40(5):1240-1262. DOI: 10.1148/rg.2020200025. View

20.

Kim D, Kim H, Kim K, Byun J, Song K, Kim J . Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol. 2014; 25(5):1375-83. DOI: 10.1007/s00330-014-3532-z. View